This article was originally published on Docwire News
Nina Shah, MD, an associate professor in the Department of Medicine at the University of California, San Francisco, discusses immunotherapy agents in the pipeline for multiple myeloma (MM) and how the potential approval of these agents could change the treatment landscape and advance combination therapy.